SPRB — Spruce Biosciences, Inc.

Summary of Spruce Biosciences Q1 2023 Earnings Call

1. Key Financial Results and Metrics

• As of December 31, 2024, Spruce reported cash and cash equivalents of $38.8 million.
• The company expects its cash runway to support operations through the end of 2025.
• There are 42.2 million shares of common stock outstanding, increasing to 60.7 million on a fully diluted basis.
• The company anticipates needing $60 million in incremental capital to reach potential approval for Tralesinidase Alfa (TA-ERT), with approximately $30 million needed for the BLA submission.

2. Strategic Updates and Business Highlights

• Spruce announced a new corporate strategy focusing on developing and commercializing TA-ERT for MPS IIIB, a rare pediatric neurodegenerative disease.
• The company acquired TA-ERT from BioMarin Pharmaceutical, assuming an exclusive worldwide license and potential milestone payments totaling $122.5 million.
• TA-ERT has received fast track designation, rare pediatric disease designation, and orphan drug designation in both the US and EU.
• The company plans to submit a BLA in the first half of 2026 and initiate a confirmatory trial with 14 patients prior to potential accelerated approval.

3. Forward Guidance and Outlook

• Spruce aims to build a specialized commercial organization for TA-ERT, estimating a team of 5 to 10 people will suffice for the US launch.
• The company projects a $10 million quarterly spend in 2025, increasing to $15 million in the following fiscal year due to BLA enabling activities and commercial preparations.
• The anticipated market for TA-ERT includes approximately 135 prevalent cases of MPS IIIB in the US, with a potential for 50% of those patients to be treated.

4. Bad News, Challenges, or Points of Concern

• Spruce's previous development efforts for CAH (Congenital Adrenal Hyperplasia) were discontinued due to failure to meet primary efficacy measures, which raises concerns about the company's ability to execute on new initiatives.
• The company has limited financial resources and will require additional funding to advance its development plans beyond 2025.
• The market environment remains volatile, which could complicate financing efforts.
• The prior sponsor of TA-ERT discontinued the program in October 2023 due to financial constraints, leading to a lack of ongoing patient treatment and raising questions about the continuity of care.

5. Notable Q&A Insights

• Management expressed confidence in the FDA's commitment to the accelerated approval pathway for TA-ERT, citing recent precedents from other companies in the MPS space.
• The confirmatory trial will focus on neurocognitive outcomes as a primary endpoint, with agreement on study design from the FDA.
• There is a strong emphasis on mapping eligible patient populations and ensuring access through early access programs prior to commercial launch.
• Pricing strategy discussions highlighted that while TA-ERT is expected to command a high price due to its therapeutic benefits, competitive pricing from other products in the MPS space will also be a factor to consider.

Overall, Spruce Biosciences is positioning itself for a significant pivot in its business strategy with the acquisition of TA-ERT, while facing financial and operational challenges that will require careful management and additional capital to navigate successfully.